MONTREAL, August 28, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announced today the acceptance of six abstracts for presentation at the 2017 International Meeting on The Molecular Biology of Hepatitis B Viruses being held September 3-7, 2017 in Washington DC (http://www.hbvmeeting.org).
These presentations will provide updates from ongoing mechanistic studies on the activity of NAPs against HBV and HDV infections and additional updates on parallel collaborations examining HBV quasispecies evolution and modelling viral dynamics in NAP treated patients.
Additionally, Replicor has been selected to present an overview of its clinical database of NAP treatment in chronic HBV and HBV/HDV co-infection at the Satellite Symposium to be held on September 7 “New HBV Antiviral and Immune Modulatory Therapies in Late Pre-Clinical/Clinical Development” which will also be featured as a poster presentation during the regular meeting.
Dr. Andrew Vaillant, CSO commented “Our clinical database is unique in terms of the number of patients we have clearing HBsAg, and the length of NAP-based combination treatment and follow-up showing the establishment of functional control persisting after therapy”. Dr. Vaillant went on to comment “we think this data is important in understanding the extent of HBsAg clearance required to restore immune function and we look forward to sharing this data with the HBV community at large”.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.